Biogen has disclosed in a Wednesday Securities and Exchange Commission filing that it has been served a subpoena by the U.S. Department of Justice, which is seeking more information regarding the company’s overseas operations.
Tag Archive for: Christopher Viehbacher
Biogen misses Q4 revenue estimates on Aduhelm costs, lower MS drug sales Published: Feb 13, 2024 By Tyler Patchen BioSpace Biogen’s fourth-quarter financial results were weighed down by declining multiple […]
Biogen Inc. said on Tuesday it would pause or discontinue studies of some experimental drugs and therapies and focus on more promising treatments, in the latest attempt by the new chief to cut costs.
Biogen is laying off an unspecified number of employees, according to a article published Monday by the Boston Business Journal.
Biogen Inc. (BIIB.O) Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer’s disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.
Biogen Inc. on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of setbacks for Alzheimer’s drug Aduhelm.
